Full metadata record
DC FieldValueLanguage
dc.creatorFontalba, A. (A.)
dc.creatorReal, P.J. (Pedro J.)
dc.creatorFernandez-Luna, J.L. (J.L.)
dc.creatorAgirre-Ena, X. (Xabier)
dc.creatorProsper, F. (Felipe)
dc.creatorRichard, C. (Carlos)
dc.date.accessioned2011-04-06T13:42:14Z-
dc.date.available2011-04-06T13:42:14Z-
dc.date.issued2006-
dc.identifier.citationFontalba, A., Real P. J., Fernández-Luna, J. L., Agirre, X. et al. Leukemia Research. 2006; 30: 1323–1326es_ES
dc.identifier.issn0145-2126-
dc.identifier.urihttp://hdl.handle.net/10171/17548-
dc.description.abstractImatinib mesylate has recently been reported to have clinical activity in the treatment of polycythemia vera (PV), suggesting the involvement of one of the kinases targeted by this inhibitor, including c-Kit and PDGFR. Activating c-Kit mutations have been identified in patients with mastocytosis and other myeloid disorders such as acute myeloid leukemia. Thus, we wanted to analyze the presence of mutations of c-Kit in polycythemia vera patients. We found that 7 out of 20 patients carried missense mutations in the c-Kit gene whereas no sequence variation was detected in 15 healthy controls.es_ES
dc.language.isoenges_ES
dc.publisherElsevieres_ES
dc.rightsinfo:eu-repo/semantics/openAccesses_ES
dc.subjectC-Kites_ES
dc.subjectPolycythemiaes_ES
dc.subjectVeraes_ES
dc.subjectMutationes_ES
dc.titleIdentification of c-Kit gene mutations in patients with polycythemia veraes_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.relation.publisherversionhttp://www.sciencedirect.com/science/journal/01452126es_ES

Files in This Item:
There are no files associated with this item.


Items in Dadun are protected by copyright, with all rights reserved, unless otherwise indicated.